It could be as simple as the following: discussions with potential partners were/are progressing more slowly than they would like, and this raise allows them to continue to move the program forward. I am guessing that strategics want to see end of phase 2 FDA correspondence to help them assess the probability of regulatory success. Has Enanta guided on when they expect to meet with the FDA?
Market Data 
Markets 
AI
